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Abstract
Objective
To evaluate the efficacy, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS;
gammaCore; electroCore, LLC, Basking Ridge, NJ) for the acute treatment of migraine in
a multicenter, double-blind, randomized, sham-controlled trial.
Methods
A total of 248 participants with episodic migraine with/without aura were randomized to
receive nVNS or shamwithin 20minutes from pain onset. Participants were to repeat treatment
if pain had not improved in 15 minutes.
Results
nVNS (n = 120) was superior to sham (n = 123) for pain freedom at 30 minutes (12.7% vs 4.2%;
p = 0.012) and 60 minutes (21.0% vs 10.0%; p = 0.023) but not at 120 minutes (30.4% vs 19.7%;
p = 0.067; primary endpoint; logistic regression) after the first treated attack. A post hoc repeated-
measures test provided further insight into the therapeutic benefit of nVNS through 30, 60, and
120 minutes (odds ratio 2.3; 95% confidence interval 1.2, 4.4; p = 0.012). nVNS demonstrated
benefits across other endpoints including pain relief at 120minutes andwas safe andwell-tolerated.
Conclusion
This randomized sham-controlled trial supports the abortive efficacy of nVNS as early as 30
minutes and up to 60 minutes after an attack. Findings also suggest effective pain relief,
tolerability, and practicality of nVNS for the acute treatment of episodic migraine.
ClinicalTrials.gov identifier
NCT02686034.
Classification of evidence
This study provides Class I evidence that for patients with an episodic migraine, nVNS sig-
nificantly increases the probability of having mild pain or being pain-free 2 hours post-
stimulation (absolute difference 13.2%).
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The multiple pharmacologic classes that are effective for the
acute treatment of migraine are sometimes limited by lack of
availability or risks of drug interactions, medication overuse,
and adverse events (AEs).1,2 Results from the American Mi-
graine Prevalence and Prevention study revealed no further
therapeutic gains of adding or switching to different triptans
or other existing treatment classes,1,3 and some patients may
be dissatisfied with the inconsistency of triptans in adequately
treating their attacks.4,5 Practical alternatives, such as non-
invasive neuromodulation therapies that are effective, safe,
and well-tolerated, are attractive for early, adjunct, or frequent
use when standard pharmacologic interventions are largely
unavailable or ineffective.1,5–7
Noninvasive vagus nerve stimulation (nVNS; gammaCore;
electroCore, LLC, Basking Ridge, NJ) has shown efficacy in
pilot studies of acute migraine treatment and is highly prac-
tical and convenient due to its strong safety and tolerability
profile.8–11 Results from a small open-label study demon-
strated 2-hour responder rates of 21% for pain freedom and
47% for pain relief after the first treated attack.9 Findings
indicated that a large randomized controlled study of nVNS as
an acute migraine treatment was warranted. Conducting this
trial according to International Headache Society (IHS)
guidelines was critical in ensuring appropriate scientific rigor
and consistency with other comparable studies.12 In align-
ment with these guidelines, objectives of the current study
were to (1) compare clinically meaningful outcomes of acute
nVNS treatment with those of a sham device in participants
with episodic migraine and (2) evaluate the safety and toler-
ability of nVNS.
Methods
Primary research question
Is nVNS effective for the acute treatment of migraine attacks
in episodic migraine? This study provides Class I evidence
that for patients with an episodic migraine, nVNS significantly
increases the probability of havingmild pain or being pain-free
2 hours poststimulation (absolute difference 13.2%).
Study design
This multicenter, randomized, double-blind, parallel-group,
sham-controlled study took place across 10 Italian sites from
January 11, 2016, through March 31, 2017. The study was
designed to compare nVNS to sham treatment and included
three 4-week periods: (1) a run-in period; (2) a double-blind
period; and (3) an open-label period. In the observational
run-in period, participants treated their migraine attacks with
standard medications according to their individual pre-
scriptions. Participants treated up to 5 migraine attacks with
nVNS or sham in the double-blind period and up to 5 addi-
tional attacks with nVNS in the open-label period; only 1
attack could be treated in a 48-hour period.
Standard protocol approvals, registrations,
and participant consents
Investigators obtained local ethics committee approval of
the protocol, which was registered at ClinicalTrials.gov
(NCT02686034). All participants provided written in-
formed consent before study initiation.
Participants
Study sites enrolled participants who were 18–75 years of age
with a previous diagnosis of migraine with or without aura
according to ICHD-3 beta criteria.13 Participants were <50
years of age at migraine onset and had an attack frequency of
3–8 attacks per month with <15 headache days per month
over the last 6 months.
Key exclusion criteria were as follows: history of secondary
headache, aneurysm, intracranial hemorrhage, brain tumors, sig-
nificant head trauma, substance abuse, addiction, syncope, or
seizure; another significant pain disorder; cardiovascular/
cerebrovascular disease; uncontrolled hypertension; psychiatric/
cognitive disorders; pregnancy; medical condition requiring oral/
injectable steroids; botulinum toxin injections in the past 6
months; head or neck nerve blocks in the past 2months; previous
migraine prevention surgery, cervical vagotomy, electrical device,
or metal cervical spine hardware implantation; current use of
opioids for more than 2 days per month; current use of simple
analgesics or nonsteroidal anti-inflammatory drugs for more than
15 days per month; current use of triptans, ergots, or combined
analgesics for more than 10 days per month; and initiation of
preventive migraine medications in the past 2 months. Partic-
ipants who entered the double-blind period were reassessed for
entry criteria.
Participants receiving preventivemigrainemedications at baseline
(or other preventive medications determined to potentially in-
terfere with the study) were required to have maintained a stable
dose and frequency of these medications during the 2 months
before enrollment and throughout the study; initiation of new
preventive medications was not permitted during this period.
Randomization and blinding
Participants were randomly assigned (1:1) to receive nVNS or
sham (variable block design [4 and 6], stratified by site)
Glossary
AE = adverse event;CI = confidence interval; ICHD-3 beta = International Classification of Headache Disorders, 3rd edition (beta
version); IHS = International Headache Society; ITT = intent-to-treat; nVNS = noninvasive vagus nerve stimulation;
PRESTO = Prospective Study of nVNS for the Acute Treatment of Migraine; SAE = serious adverse event.
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according to independent statistician-generated randomiza-
tion schedules. A third-party distributor allocated the devices
to the sites. Devices were labeled with a serial number and not
outwardly identified as active or sham. The Merge eClinical
OS Interactive Web Response system provided study site
personnel (investigator or designee) with a sequential par-
ticipant randomization number and corresponding device
serial number. A sponsor designee provided the randomiza-
tion schedule to a site-identified unblinded trainer. The
trainer was unblinded to provide participants with instruc-
tions that were specific to the assigned device and had no
further interaction with participants. This allowed for inves-
tigators and participants to remain blinded to treatment
assignments throughout the study in order to minimize po-
tential bias related to the device-specific training instructions.
Interventions
The nVNS device produces a proprietary low-voltage elec-
trical signal comprising a 5-kHz sine wave burst lasting for 1
ms (5 sine waves, each lasting 200 μs), with such bursts re-
peated once every 40 ms (25 Hz), generating a 24-V peak
voltage and 60-mA peak output current. The sham device
produces a low-frequency (0.1 Hz) biphasic signal that was
intended to be physically perceived without actually stimu-
lating the vagus nerve or generally causingmuscle contraction.
An unblinded trainer instructed the participants on electronic
diary completion and correct study device use. A follow-up
phone call at 5 days into each study period ensured adherence to
the instructions. Within 20 minutes from migraine pain onset,
participants self-administered bilateral 120-second stimulations
to the right and left sides of the neck. Participants recorded post-
treatment assessments in their diaries at 15, 30, 60, and 120
minutes and 24 and 48 hours after completion of the initial
bilateral stimulations. Participants were instructed to repeat the
bilateral stimulations if pain had not improved at the 15-minute
assessment, and participants who were not pain-free at the 120-
minute assessment had the option of administering an additional
set of bilateral stimulations. Participants were asked to wait 120
minutes before using acute rescue medication.
Study endpoints
As recommended by IHS guidelines,14 the primary efficacy
endpoint was the proportion of participants who were pain-
free without using rescue medication at 120 minutes after
study treatment completion for the first treated migraine at-
tack of the double-blind period. Key secondary and other
efficacy endpoints for the first treated attack during the
double-blind period included pain-free rates at 30 and 60
minutes; pain relief at 30, 60, and 120 minutes; mean per-
centage change in pain score from baseline to 30, 60, and 120
minutes; and the absence of associated symptoms
(i.e., nausea, vomiting, photophobia, and phonophobia) at
120 minutes. Pain relief was defined according to the IHS
guidelines for controlled studies of migraine medications as
a decrease in pain intensity from moderate (2) or severe (3)
to mild (1) or no (0) pain on a 4-point scale.14 Consistency of
response, another clinically meaningful outcome recommended
Figure 1 Participant disposition
AE = adverse event; ITT = intent-to-treat; nVNS = noninvasive vagus nerve stimulation. *Other reasons for discontinuation included inability to fulfill visits
because of injury, inability to continue the study because of family commitments, dissatisfaction with or discontinued/lack of use of the device, and
noncompliance with study procedures.
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by IHS guidelines,14 was evaluated during the double-blind
period by calculating ≥50% responder rates at 120 minutes for
both pain freedom and relief in those with at least 2 treated
migraine attacks. Pain freedom and pain relief were also evalu-
ated at 120minutes after the first treated attack in the open-label
period, as was the consistency of response for those who treated
at least 2 attacks during this period. Additional outcomes in-
cluded blinding effectiveness, participant satisfaction (1, ex-
tremely satisfied; 5, not at all satisfied), participant willingness to
recommend the device to a friend or familymember, and ease of
device use (1, very easy; 4, very difficult). The safety and tol-
erability of nVNS was assessed by comparing rates of AEs,
adverse device effects, and serious adverse events (SAEs) among
the nVNS group and controls.
Statistical methods
A sample size of 232 participants (116 per treatment arm) was
determined to provide 90% power to demonstrate statistical
significance for the primary endpoint, assuming a sham pain-
free rate of 18%, a treatment difference of 20%, an α value of
0.05, and an attrition rate of 10%.
Descriptive statistics were used for both continuous variables
(means and 95% confidence intervals [CIs]) and categorical
variables (frequency counts, percentages, and 95% CIs). Each
attack was assessed separately, with responder rates based
solely on pain intensity if medication use data were missing.
Missing pain intensity data were imputed using the last ob-
servation carried forward. Participants who did not provide
data on associated symptoms were excluded from symptom-
specific analyses.
Statistical efficacy analyses (nVNS vs control) were conducted
on the intent-to-treat (ITT) population, defined as all ran-
domized participants who treated at least 1 migraine attack in
the double-blind period. A logistic regression analysis was
Table 1 Demographics and participant/attack characteristics
Characteristic nVNS (n = 120) Sham (n = 123)
At baseline
Age, y 38.8 ± 11.0 39.6 ± 11.8
Age at migraine onset, y 29.4 ± 11.2 28.5 ± 11.5
Female, n (%) 95 (79.2) 91 (74.0)
Caucasian, n (%) 120 (100.0) 123 (100.0)
Migraine type, n (%)
Migraine with aura 8 (6.7) 9 (7.3)
Migraine without aura 112 (93.3) 114 (92.7)
Attacks in the last 4 weeks, n 5.4 ± 1.7 5.3 ± 1.7
Headache days in the last 4 weeks, n 6.3 ± 2.3 6.2 ± 2.1
Attacks per month in the last 6 months, n 5.4 ± 1.5 5.4 ± 1.5
Acute migraine medication use per month, d 5.6 ± 1.7 5.3 ± 1.7
Preventive medication use, n (%) 42 (35.0) 35 (28.5)
At attack onseta
Migraine attack severity (first treated attack), n (%)b
Mild 40 (33.6) 46 (38.7)
Moderate 51 (42.9) 55 (46.2)
Severe 28 (23.5) 18 (15.1)
Migraine attack severity (all treated attacks), n (%)b
Mild 113 (31.5) 105 (31.9)
Moderate 156 (43.5) 166 (50.5)
Severe 90 (25.1) 58 (17.6)
Abbreviation: nVNS = noninvasive vagus nerve stimulation.
Intent-to-treat population. Data are mean ± SD unless otherwise indicated.
a Participants with no reported severity at attack onset are excluded from this analysis.
b First treated attack: nVNS, n = 119; sham, n = 119; all treated attacks: nVNS, n = 359; sham, n = 329.
Neurology.org/N Neurology | Volume 91, Number 4 | July 24, 2018 e367
included in the primary endpoint (pain freedom at 120minutes
for the first attack in the double-blind period) with adjustment
for the participants’ baseline pain score, use of preventive
therapies, and presence of aura andwas repeated for the 30- and
60-minute time points; the presence of aura was not considered
in the 30-minute analysis because of model fit issues. A post hoc
repeated-measures analysis using generalized linear mixed-
effects regression models was conducted to gain further insight
from all of the data collected at multiple time points through
the 120-minute time point of the primary efficacy analysis. The
repeated-measures analysis was also adjusted for baseline pain
score, use of preventive therapies, and presence of aura. Mean
percentage changes in pain score were compared between
treatment groups using 2-sample t tests. The remaining sec-
ondary and other analyses reported were evaluated using the χ2
test or Fisher exact test, as appropriate. Two-sided p values
<0.05 were considered statistically significant. Use of rescue
medication before the 120-minute assessment was considered
a study treatment failure.
Blinding analyses were performed using the Bang blinding
index. Safety analyses were conducted on the safety
population, defined as all enrolled participants. All data were
analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC).
Data availability
Any data not published within this article will be publicly avail-
able at ClinicalTrials.gov with the identifier NCT02686034.
Individual participant data will not be shared.
Results
Participants
In the Prospective Study of nVNS for the Acute Treatment of
Migraine (PRESTO), 285 participants were enrolled, 248
were randomized, and 243 formed the ITT population (figure
1). A total of 237 participants from the ITT population
completed the open-label period, with 219 of these treating at
least 1 attack during this period. Demographic and baseline
characteristics were generally well-balanced between the
nVNS group and controls (table 1). A higher proportion of
participants in the nVNS group treated their first attack when
its intensity was severe (p = 0.254) and were using preventive
medications (p = 0.273). The most commonly used
Figure 2 Responder rates after the first treated attack during the double-blind period
(A) Pain freedom and (B) pain relief. CI = confidence
interval; nVNS = noninvasive vagus nerve stimulation.
Data for no. of participants in (A) are unadjusted
numbers. *Statistically significant. **Primary endpoint.
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preventive medications were topiramate, vitamin B2, magne-
sium, and propranolol.
Pain-free responder rates
For the first treated migraine attack, the proportion of par-
ticipants who became pain-free was significantly higher with
nVNS than with sham at 30 and 60 minutes but not at 120
minutes (primary endpoint) (figure 2A). A repeated-
measures test examined the inconsistency between the 120-
minute finding and the 30- and 60-minute findings and found
nVNS to be superior to sham for the pain-free outcome
through 30, 60, and 120 minutes (odds ratio 2.3; 95% CI 1.2,
4.4; p = 0.012).
Responder rates for pain relief
Responder rates for pain relief at 120 minutes were signifi-
cantly higher with nVNS than with sham for the first treated
migraine attack (figure 2B). Responder rates for pain relief
were numerically higher with nVNS at 30 and 60 minutes, but
these differences were not significant (figure 2B).
Percentage pain intensity reductions
Mean percentage pain intensity reductions for the first attack
were significantly more pronounced with nVNS than with
sham at 60 and 120 minutes (figure 3).
Consistency of response
Proportions of participants who responded at 120 minutes for
≥50% of their attacks were significantly higher with nVNS
than with sham for both pain freedom and pain relief
(figure 4).
Associated symptoms
As expected with the early treatment of attacks in this study,
relatively low percentages of participants were experiencing
an associated symptom at the time of initial treatment
(vomiting, 6.6%; nausea, 30.5%; photophobia, 46.9%;
phonophobia, 43.2%). The number of participants who did
not report vomiting at 120 minutes after the first treated
attack was higher in the nVNS group (6/8 [75.0%]) than in
controls (3/8 [37.5%]) (p = 0.315). Proportions of par-
ticipants who became nausea-free (nVNS, 14/35 [40.0%];
sham, 16/39 [41.0%]; p = 0.929), photophobia-free
(nVNS, 20/53 [37.7%]; sham, 23/61 [37.7%]; p =
0.997), or phonophobia-free (nVNS, 16/48 [33.3%];
sham, 24/57 [42.1%]; p = 0.357) at 120 minutes after the
first treated attack were similar among the nVNS group and
controls.
Blinding
After the first treatment and at the end of the double-blind
period, participants indicated the treatment they thought
they had received (nVNS, sham, do not know); guesses
were generally similar among the nVNS group and
controls (figure 5). After the first treatment, Bang
blinding index estimates for nVNS and sham indicated
successful blinding (i.e., inclusion of zero in the 95% CI)
(figure 5).
Device use and perceptions
Almost all participants (98%) administered at least 1 stimu-
lation and were adherent to the treatment instructions, but
most participants did not administer repeat stimulations for
the first attack at 15 minutes as instructed (nVNS, 60.8%;
sham, 60.2%) or optionally at 120 minutes (nVNS, 95.8%;
sham, 93.5%).
The percentage of participants who rated the treatment as
a little satisfying or better at the end of the double-blind
period was higher for nVNS (72.0%) than for sham (63.9%),
as was the percentage of participants who would recommend
their study device to a friend or family member (nVNS,
60.2%; sham, 46.7%). Approximately 96% of participants in
each treatment group reported that their device was some-
what or very easy to use.
Efficacy findings from the open-label period
Therapeutic benefits seen with nVNS in the double-blind
period were sustained after an additional 4 weeks of acute
nVNS use in the open-label period. Findings were con-
sistent after the first treated attack of the double-blind and
open-label periods for pain-free response (30.4% and
27.9%, respectively) and pain relief (40.8% and 43.4%,
respectively). The consistency of response to nVNS was
also maintained from the double-blind period (pain free-
dom, 32.4%; pain relief, 47.6%) to the open-label period
(pain freedom, 26.8%; pain relief, 41.8%).
Safety and tolerability
Acute nVNS therapy demonstrated a highly favorable
safety and tolerability profile (table 2). The most common
AEs were application site discomfort and nasopharyngitis
Figure 3Mean percentage pain score reductions
Changes are from baseline for the first treated attack in the double-blind
period; post hoc analysis. CI = confidence interval; nVNS = noninvasive vagus
nerve stimulation. *Statistically significant.
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in the nVNS group and application site erythema and pain,
dizziness, flu-like symptoms, and nasopharyngitis among
controls. Participants reported no SAEs during the study.
Only 2 participants, both controls, discontinued from the
study due to AEs.
Discussion
The PRESTO trial is one of the largest randomized, double-
blind, sham-controlled studies of a noninvasive neuro-
modulation device for the acute treatment of migraine.2 In the
absence of guidelines for evaluating neuromodulation in mi-
graine, this trial was designed and conducted using stringent
IHS recommendations for evaluating migraine medications.14
Our adherence to the current standards for pharmacologic
trials included the use of 2-hour pain freedom as the primary
endpoint, which is less vulnerable to the placebo/sham effect
compared with pain relief.4,14,15
nVNSwas superior to sham in aborting the first treated attack at
30 and 60minutes but not at 120minutes. A repeated-measures
test provided additional insight into the primary endpoint by
supporting the superiority of nVNS over sham in achieving pain
freedom through 30, 60, and 120 minutes. The pain-free re-
sponder rate at 120 minutes in the nVNS group (30.4%)
was consistent with those generally seen in previous studies
evaluating the efficacy of oral triptans (14%–42%)4,16–18 and of
potent nonsteroidal anti-inflammatory drugs (15%–25%).19–21
Higher 2-hour pain-free rates of oral triptans (47%–68%) have
been reported in patients with mild-intensity migraines who
also generally had higher 2-hour pain-free placebo rates and in
patients treated with higher-dose regimens,17 which often fur-
ther increase the risk of adverse effects.22 Taken together,
findings of this large, rigorous, well-controlled trial strongly
suggest that nVNS is effective and has benefits consistent with
standard drug options but with the added benefit of an ex-
tremely benign adverse effect profile and the flexibility to be
used for multiple attacks without the risk of medication overuse
or drug-related adverse effects. As a nonpharmacologic option,
nVNS can also be utilized in combination with any existing
medication.
A higher percentage of participants in the nVNS group treated
their first attack while it was severe in intensity. This differ-
ence, although not statistically significant, suggests a clinically
meaningful bias toward more severe pain at the time of
treatment in the nVNS group that may have moderated the
therapeutic gain seen in the study results. Associated symp-
toms had not yet emerged in many participants as nVNS or
sham treatment was initiated within 20 minutes from mi-
graine pain onset, which limits statistical power for evaluating
these symptoms. The early treatment design likely contrib-
uted to the lack of superiority of nVNS in improving associ-
ated symptoms, consistent with challenges in other
noninvasive device studies.23,24 Treatment responses may
have also been mitigated due to the limited use of repeat
stimulations. Additional stimulations appeared to improve
efficacy in previous studies and carry minimal risks given the
favorable safety and tolerability of nVNS.11,25–29 A possible
explanation for why most participants in the current study did
not administer repeat stimulations as instructed may involve
a perceived rapid pain relief from the initial stimulations that
led to a lack of need or motivation to administer the additional
stimulations.
The limitations of this study include the selection of an ap-
propriate sham device, which is a consistent challenge in
neuromodulation studies.30 The sham device in this study had
an active signal that was strong enough to be perceived but
was not intended to stimulate the vagus nerve, as recom-
mended in published literature.30 The apparent strength of
the sham signal helped to maintain blinding but could have
conceivably elevated the effects of sham treatment across all
endpoints, limiting the ability of clinically meaningful active
therapeutic gains to achieve statistical superiority. We hy-
pothesize that the higher-than-expected sham results could
represent either a psychobiological placebo effect31 or
a physiologically active response potentially related to an
unanticipated low level of vagal or other activity generated by
an active sham signal being applied to the neck.
The mechanism of action of nVNS in the treatment of mi-
graine is largely elusive and likely multifactorial. Preclinical
data have demonstrated that this therapy inhibits the trige-
minovascular pathway and suppresses extracellular glutamate
in the central nervous system.25,32 A study that used a vali-
dated migraine-specific animal model demonstrated that di-
rect activation of the vagus nerve, which has been shown to be
Figure 4 ≥50% responder rates at 120 minutes during the
double-blind period
CI = confidence interval; nVNS = noninvasive vagus nerve stimulation.
*Statistically significant. **Post hoc analysis.
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elicited by nVNS,33,34 suppressed the acute nociceptive acti-
vation of trigeminocervical neurons.25 In a separate study
using an established rodent model of chronic trigeminal
allodynia, nVNS reversed the elevation in extracellular glu-
tamate, a marker of increased pain, within the trigeminal
nucleus caudalis.32 These studies suggest that direct activation
of the vagus nerve by nVNS treatment facilitates central in-
hibition in the trigeminovascular system, contributing to the
clinical efficacy seen in the current study.
The scientific rigor of the large PRESTO trial and its adher-
ence to IHS guidelines for pharmacologic studies allow for the
consideration of nVNS in the context of currently available
acute treatment options for migraine.12,14,17 Our results
provide an option for both headache centers and the larger
migraine community to address the need for further optimi-
zation of the control of migraine attacks without any
added adverse effects or the risk of medication overuse.35
PRESTO and a forthcoming randomized sham-controlled
Figure 5 Blinding
nVNS = noninvasive vagus nerve stimulation. *Inclusion of
zero in the 95% confidence interval (CI) indicates successful
blinding.
Table 2 Incidence of adverse events (AEs) and adverse device effects (ADEs) (all study periods)
AEs and ADEs nVNS (n = 122) Sham (n = 126)
≥1 AE 22 (18.0) 23 (18.3)
≥1 ADE 7 (5.7) 10 (7.9)
≥1 SAE 0 0
AEs occurring in ≥2% of participants in any treatment group
General disorders and administration site conditions
Application site discomfort 3 (2.5) 1 (0.8)
Application site erythema 0 3 (2.4)
Application site pain 0 3 (2.4)
Infections and infestations
Influenza 0 3 (2.4)
Nasopharyngitis 2 (1.6) 3 (2.4)
Nervous system disorders
Dizziness 0 3 (2.4)
Abbreviations: nVNS = noninvasive vagus nerve stimulation; SAE = serious adverse event.
Safety population. Data are n (%) of participants.
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study of nVNS for the prevention of episodic migraine
(ClinicalTrials.gov identifier: NCT02378844) may also help
the migraine community by informing future recom-
mendations regarding neuromodulation trials.
nVNS is a novel, flexible therapeutic approach for the acute
treatment of migraine attacks. The therapeutic benefit of nVNS
was consistent across several important, clinically relevant end-
points andwas similar to that of oral triptans, as demonstrated by
similar 2-hour pain-free responder rates.4,16,18 Its combination of
efficacy and consistent safety and tolerability, established over
multiple studies,11,26–29 makes it an attractive option for early
and frequent use. nVNS may be used in conjunction with
existing treatments without any drug interactions or as mono-
therapy, potentially delaying or decreasing the need for medi-
cations that can be limited by lack of availability, inconvenience,
or AEs.1,2,5,36 nVNS offers a convenient complementary treat-
ment option that is easy to use, has no pharmacologic AEs, and
preserves the flexibility to use standard medications when
needed. Findings from this randomized sham-controlled trial
demonstrate the efficacy of nVNS for aborting attacks as early as
30 minutes and up to 60 minutes and for relieving pain at 120
minutes in the acute treatment of episodic migraine with or
without aura. This study also confirms the practicality and strong
safety and tolerability profile of nVNS.
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